These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6721984)

  • 21. Rectal drug administration: clinical pharmacokinetic considerations.
    de Boer AG; Moolenaar F; de Leede LG; Breimer DD
    Clin Pharmacokinet; 1982; 7(4):285-311. PubMed ID: 6126289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Principles of pharmacokinetics.
    Tucker GT
    Ciba Found Symp; 1979; (74):13-33. PubMed ID: 261681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption.
    Deng J; Jhandey A; Zhu X; Yang Z; Yik KFP; Zuo Z; Lam TN
    PLoS One; 2018; 13(8):e0203361. PubMed ID: 30169515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of route of administration on drug disposition.
    Riegelman S; Rowland M
    J Pharmacokinet Biopharm; 1973 Oct; 1(5):419-34. PubMed ID: 4787618
    [No Abstract]   [Full Text] [Related]  

  • 25. The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.
    Dawson M; Braithwaite PA; Roberts MS; Watson TR
    Br J Clin Pharmacol; 1985 Jan; 19(1):79-86. PubMed ID: 3978023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of the analysis and interpretation of bioavailability studies in man.
    Wagner JG
    Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man.
    Taylor G; Houston JB; Shaffer J; Mawer G
    Br J Clin Pharmacol; 1983 Mar; 15(3):287-93. PubMed ID: 6849764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basic pharmacokinetics.
    Levy RH; Bauer LA
    Ther Drug Monit; 1986; 8(1):47-58. PubMed ID: 3515640
    [No Abstract]   [Full Text] [Related]  

  • 31. Kinetics of drug metabolism inhibition: use of metabolite concentration-time profiles.
    Shaw PN; Houston JB
    J Pharmacokinet Biopharm; 1987 Oct; 15(5):497-510. PubMed ID: 3694494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of gamma distributed residence times in pharmacokinetics.
    Weiss M
    Eur J Clin Pharmacol; 1983; 25(5):695-702. PubMed ID: 6662168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolite pharmacokinetics: the area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites.
    Pang KS
    J Pharmacokinet Biopharm; 1981 Aug; 9(4):477-87. PubMed ID: 7310645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of dipyrone in man; role of the administration route.
    Asmardi G; Jamali F
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):121-5. PubMed ID: 4043141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfer functions obtained by the rule of corresponding fractional areas.
    Dost FH; von Hattingberg HM
    Eur J Clin Pharmacol; 1971 Sep; 3(4):252-4. PubMed ID: 5151310
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the "first pass" after oral administration.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):828-33. PubMed ID: 16489605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimating reduced availability due to first pass elimination from relative total clearance and renal clearance.
    Brockmeier D
    Eur J Clin Pharmacol; 1988; 35(4):397-400. PubMed ID: 3197748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presystemic elimination of drugs: theoretical considerations for quantifying the relative contribution of gut and liver.
    Minchin RF; Ilett KF
    J Pharm Sci; 1982 Apr; 71(4):458-60. PubMed ID: 7086660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.